When it comes to investing in the stock market, it’s easy to get caught up in the daily fluctuations and forget about the bigger picture. Despite a recent dip in the S&P 500, the overall market environment remains positive, with the benchmark rising 17% so far this year. In times like these, it’s important to look for opportunities that have the potential to grow in the long term.
Two such opportunities are biotech company Moderna (NASDAQ: MRNA) and pharma giant Pfizer (NYSE: PFE). While both companies saw significant success with their COVID-19 vaccines, their stocks have since dropped more than 50% from their peaks. However, there’s more to these companies than just one product. Moderna, in particular, has a strong pipeline of promising candidates that could drive future growth. Pfizer, on the other hand, has been making strategic acquisitions and investments in research and development to position itself for a comeback.
Moderna’s success with its coronavirus vaccine propelled the company to new heights, but as vaccine demand declined, so did the stock price. However, with multiple vaccines in the pipeline, as well as other investigational drugs in development, Moderna has the potential to introduce several new treatments in the near future. This could lead to significant growth for the company down the road.
Pfizer, on the other hand, faced challenges with declining revenue and earnings due to the drop in COVID-19 product sales and looming patent expirations. However, the company has taken steps to address these issues through smart acquisitions and investments in research and development. With a strong pipeline of promising candidates and a forward dividend yield of 5.7%, Pfizer presents an attractive opportunity for value and income investors.
Both Moderna and Pfizer offer long-term potential for investors looking to capitalize on their current discounted stock prices. As the bull market continues, these companies could regain momentum and deliver solid returns for patient investors.
If you’re considering investing in Moderna or any other stock, it’s important to do your research and consider all factors before making a decision. The Motley Fool Stock Advisor, for example, provides valuable insights and recommendations on the best stocks to buy now. By following their guidance and staying informed, you can make more informed investment decisions and potentially achieve significant returns in the long run.
In conclusion, despite recent market fluctuations, there are opportunities for investors to capitalize on the long-term potential of companies like Moderna and Pfizer. By staying informed, conducting thorough research, and seeking expert guidance, investors can position themselves to benefit from the ongoing bull market and achieve their financial goals.